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Immunitya b s t r a c t
The vast majority of infection with cryptococcal species occurs with Cryptococcus neoformans in the
severely immunocompromised. A signiﬁcant exception to this is the infections of those with apparently
normal immune systems by Cryptococcus gattii. Susceptibility to cryptococcosis can be broadly cate-
gorised as a defect in adaptive immune responses, especially in T cell immunity. However, innate
immune cells such as macrophages play a key role and are likely the primary effector cell in the killing
and ultimate clearance of cryptococcal infection. In this review we discuss the current state of our under-
standing of how the immune system responds to cryptococcal infection in health and disease, with ref-
erence to the work communicated at the 9th International Conference on Cryptococcus and
Cryptococcosis (ICCC9). We have focussed on cell mediated responses, particularly early in infection,
but with the aim of presenting a broad overview of our understanding of immunity to cryptococcal infec-
tion, highlighting some recent advances and offering some perspectives on future directions.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Cryptococcus neoformans and Cryptococcus gattii are environmen-
tal yeasts that cause opportunistic infection. Themost common and
serious type of cryptococcal disease is pulmonary cryptococcosis
that is uncontrolled and leads to cryptococcal meningitis (CM) or
meningoencephalitis. CM is almost exclusively observed in those
with severely impaired immunity. Rarely other forms of cryptococ-
cal infection are seen (e.g. cutaneous infection, peritonitis;
(Christianson et al., 2003; El-Kersh et al., 2013) but this review will
focus on infection and immunity to CM (Jarvis and Harrison, 2007).
C. neoformans infection is a leading cause of mortality within
AIDS patients worldwide, particularly in sub-Saharan Africa (Park
et al., 2009). In addition to HIV infected individuals, C. neoformans
is also associated with other immunocompromised groups such as
those with haematopoietic malignancy, solid transplant patients
(e.g. glucosteroid therapy) and therapy for rheumatoid arthritis
(e.g. anti-TNFa mAb). In contrast, C. gattii is capable of infecting
immunocompetent individuals, most notably in the Vancouver
Island outbreak (Kidd et al., 2004), and is generally absent in the
immunocompromised (Chen et al., 2000; Mitchell and Perfect,
1995). There are a number of counter examples e.g. C. gattii infec-
tion of HIV infected individuals (Springer et al., 2014; Steele et al.,2010) and certain C. neoformans genotypes infecting the immuno-
competent (Chau et al., 2010). C. neoformans is found globally and
has been isolated from pigeon excrement, soil and rotting vegeta-
bles, whereas C. gattii is predominantly restricted to tropical and
sub-tropical areas, and is associated with eucalyptus trees
(Bovers et al., 2008; Voelz and May, 2010).2. Overview of host immunity during cryptococcosis
In this section we introduce the broad concepts of the immune
response and pathogenesis of cryptococcosis before exploring each
part in greater detail in the sections below. Pulmonary cryptococcal
infectionwill occur only if fungal cells, environmentally acquired by
inhalation, are deposited deep in the lungs. After deposition within
the lung, alveolar macrophages (AMs), tissue resident macrophages
that will removemicroorganisms and other particulates, will be the
ﬁrst cells to encounter the cryptococci andwill respond by internal-
ising them through phagocytosis (Goldman et al., 2001). Following
phagocytosis AMs will ideally kill the microorganisms and initiate
and modulate the appropriate wider immune response. This will
include the release of cytokines, activation and recruitment of other
immune cells and presentation of antigen.
Due to the resolving sub-clinical or mild nature of the infection
in immunocompetent individuals there is limited data on the nor-
mal immune response to C. neoformans. Cryptococcal infections are
occasionally identiﬁed due to medical examination for other symp-
toms or conditions. In these cases cryptococci are enclosed within
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group of immune structures, commonly recognised as macrophage
like cell clusters surrounded by lymphocytes. Their primary func-
tion is to control and remove infections but are also seen in a num-
ber of immune diseases (Rose et al., 2014). Cryptococcal
granulomas are compact, with macrophages, multinucleated giant
cells (both containing intracellular yeasts) and CD4+ lymphocytes
(Shibuya et al., 2005, 2002). These granulomas will typically
resolve over a period of weeks or months without clinical interven-
tion. Evidence of childhood infection (cryptococcal antibody proﬁle
increasing with age) suggests latent infection, or repeated infection
(Goldman et al., 2001). In addition, decline of immune efﬁciency as
a trigger for the reemergence of a dormant cryptococcal infection,
potentially suggests that cryptococci are able to escape degrada-
tion and remain within an individual for long periods of time
(Garcia-Hermoso et al., 1999).
It is clear from both the clinic and experimental models of cryp-
tococcosis that T cell responses are key to the control of cryptococ-
cal infection. The major defect in the patient groups at risk of
developing cryptococcal meningitis is in the CD4+ T helper system.
Therefore, a very different response in the lung is seen in individ-
uals with AIDS. Loosely aggregated giant cells are seen but crypto-
cocci are typically extracellular and there is signiﬁcant
proliferation in the alveolar spaces (Shibuya et al., 2005, 2002). If
cryptococcal infection is not controlled in the lungs then it will dis-
seminate throughout the body, with particular preference for the
central nervous system (CNS). Infection of the CNS results in life
threatening meningitis and/or meningoencephalitis, with very
high mortality without treatment (Bovers et al., 2008; Mitchell
and Perfect, 1995). The route and mechanism of spread to the
CNS has not been directly demonstrated, however, it is likely
through the blood as the lymphatic system has no access to the
brain (Liu et al., 2012; Iliff and Nedergaard, 2013).3. The anatomical and upper respiratory defences of the lungs
and the infectious propagule of cryptococcosis
The human respiratory system is highly adapted to removing
air borne contaminants while maintaining airﬂow for efﬁcient
gas exchange. The combination of airﬂow turbulence, the physical
epithelial mucosal barrier, the trapping of particulates in mucus
and their subsequent removal via mucociliary transport, results
in the nose and upper airways largely preventing entry of particles
greater than 2 lm (Nicod, 2005). As the lungs are able to exclude
particles greater than 2 lm the infectious agent in cryptococcal
infection is hypothesised to be the spore or desiccated yeast cell
as they will be small enough to travel deep in the lower respiratory
tract (Botts and Hull, 2010; Velagapudi et al., 2009).
Furthermore, the airways are highly populated by dendritic cells
(DCs) that clear microorganisms through phagocytosis, and there
are large quantities of the immunoglobin IgA that function to bind
toxin and viral particles as well as impede bacterial invasion of
epithelial cells (Nicod, 2005). While upper airway DCs may play a
role in preventing cryptococcal yeast cells from getting deep within
the lungs, there is no evidence that airway IgA is required for pre-
vention of cryptococcal infection. However, it is intriguing to spec-
ulate whether upper airway DCsmay represent an alternative route
of primary infection for the immunocompromised.4. Lung surfactant as a barrier to cryptococcal infection
The inner surface of alveoli are covered in a ﬁlm of surfactant
that functions to ensure the alveoli in the lung are capable of full
re-inﬂation, through maintenance of surface tension (Schurch
et al., 1992). Surfactants are also known to play a role in the lungimmune defence with particles deposited within the lung being
pulled towards the alveoli wall by the surfactant promoting the
interaction of pathogens and surfactant proteins (Schurch et al.,
1992). Surfactant proteins SP-A and SP-D are members of the
immune collectins. They bind to pathogens and promote macro-
phage and neutrophil immune function by opsonising pathogens
and increasing phagocytosis (Kishore et al., 2005; Wright, 2004).
Both SP-A and SP-D preferentially bind to pathogens over host cells
through favoured binding to pathogen associated molecules e.g.
mannose (Kishore et al., 2005).
SP-A and SP-D are known to bind viral, bacterial and fungal
pathogens, including C. neoformans (Schelenz et al., 1995). SP-A
and SP-D bind both acapsular and encapsulated C. neoformans
but the effect of binding differs. SP-A bound to encapsulated yeast
was not beneﬁcial to the host, as a murine SP-A knockout model
showed no difference in survival to wild type (Giles et al., 2007).
This suggests that SP-A will have little effect once C. neoformans
has induced capsule synthesis and may be one mechanism by
which the cryptococcal capsule promotes virulence through block-
ing the action of SP-A. Similarly, SP-D can bind both acapsular and
encapsulated yeast but there is only increased phagocytosis of
acapsular yeast in vivo (Geunes-Boyer et al., 2009). There is evi-
dence that SP-D promotes virulence of encapsulated C. neoformans
as SP-D knock-out mice were better able to control cryptococcal
infection than wild-type mice (Geunes-Boyer et al., 2012, 2009).
Two possible explanations for this are that SP-D protects crypto-
cocci from macrophage mediated degradation (so far only demon-
strated in vitro) and that SP-D promotes the recruitment of
eosinophils that may be detrimental to the control and clearance
of pulmonary cryptococcosis (Holmer et al., 2014).
5. Phagocytosis of cryptococci by macrophages and dendritic
cells
If spores or yeast cells enter the alveolar spaces they will
encounter alveolar macrophages (AM). There are a number of dif-
ferent subsets of both macrophages (and DCs) that are present in
the lungs (Guilliams et al., 2013), but for the purpose of this review
we will refer generally to macrophages and DCs.
Macrophage control of cryptococci is essential early in infection
with depletion of AMs in the lungs of rats (a normally resistant
host) leading to high fungal burden and dissemination following
intratracheal infection (Shao et al., 2005). Interestingly, it has been
recently demonstrated that phagocytosis in vitro can be associated
with fungal burden in a patient cohort, where increased uptake by
macrophages was associated with poor prognosis (Sabiiti et al.,
seminar presentation 9.5, ICCC9; Sabiiti et al., 2014). However, both
the mechanism governing the difference in phagocytic uptake of
these strains, and the point during infection where the phagocyto-
sis phenotype is critical in human infection, are yet to be identiﬁed.
Furthermore, in mice deﬁcient in macrophages and DCs there were
increased numbers of PMNs and B cells in response to cryptococcal
infection. Neutrophils and B cells alone were unable to control the
infection and their continued presence and activation is potentially
highly damaging to the host (Osterholzer et al., 2009).
The uptake of cryptococci by phagocytes in vitro is enhanced by
the presence of antibody and/or complement as opsonin. Opsonin
provides an adapter between receptors on phagocytes and the sur-
face of the microorganism. The Fc receptors on macrophages and
dendritic cells bind to the constant region of antibody and the bind-
ing of a sufﬁcient cluster of Fc receptors activates actin mediated
uptake of the microorganism. Fc receptor signalling does not only
lead to uptake but also can modulate the activation and signalling
state of the phagocyte. Recently, a polymorphism in the antibody
binding receptor, Fc gamma receptor 3A (FcGR3A), has been identi-
ﬁed as a risk factor for male, HIV infected individuals (Rohatgi et al.,
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combined with the FcGR3A polymorphism having a higher afﬁnity
for these immune complexes, may result in increased phagocytosis,
and therefore greater intracellular proliferation and spread within
the host. A second polymorphism has also been identiﬁed in
FccRIIB in a non HIV cryptococcal meningitis cohort (Zhu et al.,
seminar presentation 3.1, ICCC9; Hu et al., 2012).
Similarly to Fc mediated uptake, complement binds to a hetero-
dimer of integrin receptors (CR3; CD11b/CD18) and activates actin
mediated phagocytosis. The complement cascade completes three
key roles during pathogen infection: Opsonisation, direct killing of
pathogens and recruitment of inﬂammatory cells. The complement
cascade converges with the production of C3 convertase, and sub-
sequent creation of C3b, via three main pathways; classical, lectin
and alternative, which in turn lead to production of C5a and C5b.
The alternative pathway mediates the role of complement protein
in host defence against C. neoformans, although nonencapsulated
cryptococci are able to activate the classical pathway (Kozel
et al., 1991; Mershon-Shier et al., 2011). Cryptococcal capsule
accumulates C3 via the alternative pathway and deposition of C3
near the surface is needed for efﬁcient phagocytosis. However, if
C3 is evenly distributed throughout the capsule increased volume
of capsular polysaccharide will reduce the amount on the surface
resulting in reduced complement mediated phagocytosis (Gates
and Kozel, 2006; Zaragoza et al., 2003). To add to this, recently a
cryptococcal hydrolytic enzyme, lactonohydrolase (LHC1), was
shown to combat the complement cascade through inducing cap-
sular changes which reduces C3 deposition on the capsule, a lhc1
mutant that had increased C3 deposition and decreased virulence
(Park et al., 2014). Another complement protein, C5 is also impli-
cated, with mice strains more susceptible to cryptococcal infection
when C5 was not present in their plasma (Rhodes et al., 1980).
Phagocyte pattern recognition receptors (PRRs) are important in
phagocytosis both in combination and independent of opsonic
recognition. PRR bind to speciﬁc components of microbes, usually
on their surface (exceptions being those receptors that bind to
nucleic acid) and although often implicated in phagocytosis, are
not all direct activators of pathogen internalisation. Mannose and
the beta glucan are the primary pathogen recognition motifs for
PRR mediated recognition and uptake of cryptococci. However,
the polysaccharide capsule will interfere sterically and chemically
with the recognition of these motifs. As the capsule is likely to be
very small or absent in the infectious propagule, cryptococcal
mannoprotein and beta glucan will be determinants in early inter-
actions in the lung. In support of this, mannose receptor knockout
mice are more susceptible to infection and show reduced CD4+ T
cell proliferation in response to cryptococcal mannoprotein.
Uptake of cryptococcal mannoprotein by DCs was not affected
most likely through alternative sampling mechanisms such as anti-
gen presentation from the phagosome or environmental sampling
via macropinocytosis (Dan et al., 2008).
Recognition via scavenger receptor A (SR-A) (classically a recep-
tor for low-density lipoprotein but which also interacts with a
number of pathogens (Mukhopadhyay and Gordon, 2004)) appears
to promote a Th2 immune proﬁle. The SR-A deﬁcient mouse
demonstrated a better host response in terms of fungal clearance
coupled with decreased IL4 and IL13 production (Qiu et al.,
2013). In contrast, the class B scavenger receptors CD36 and
SCARF may be a requirement for pro inﬂammatory Il-1beta, as
the absence of CD36 resulted in a modest reduction in survival in
the susceptible C57BL/6 stain after acute intravenous infection
(Means et al., 2009). These two studies represent the best evidence
that the speciﬁc phagocytic receptor involved in uptake of crypto-
cocci into macrophages may directly regulate immune signalling
and therefore the outcome of infection. This is, potentially, a highly
signiﬁcant area of Cryptococcus research but there are stillfundamental gaps in our understanding, for example, a direct
demonstration that scavenger receptors mediate the uptake of
cryptococci in vivo.
Toll like receptors (TLRs) are a highly conserved group of PRRs
conserved across vertebrates (O’Neill, 2004). The TLR9 deﬁcient
mouse showed reduced CCL7 production (Cheng et al., 2014), and
restoration of CCL7 over the ﬁrst week of infection relieved the
associated suppression of interferon gamma and recruited DC
numbers (Qiu et al., 2012). However, restoration of CCL7 was insuf-
ﬁcient to suppress increased fungal burden. How TLR9 is activated
by cryptococci when it classically responds to unmethylated CpG
dinucleotides in prokaryotes is not known, although activation of
TLR9 by other eukaryotic pathogens has been described
(Nakamura et al., 2008). The roles of TLR2 and TLR4 have been
investigated but currently their role appears minor in respect to
overall control of cryptococcal infection (Biondo et al., 2005;
Nakamura et al., 2006). Treatment of microglia cells with agonists
to TLRs 2, 3, 4 and 9 increased pro inﬂammatory cytokines in
response to cryptococci but the physiological relevance of this is
not clear (Redlich et al., 2013).
Recently, another class of PRR, related to the TLRs, the intracel-
lular NOD like receptors have been implicated in cryptococcal
infection. Acapsular cryptococcal cells were able to activate
NLRP3, requiring direct cell wall contact. Mice deﬁcient in Nlrp3
had reduced inﬁltration of leukocytes into the lung and increased
fungal burden. Cryptococcal capsule is able to block this interac-
tion again suggesting that PRR interactions will be especially
important early in infection (Meng, seminar presentation 7.1,
ICCC9; Guo et al., 2014).
6. Intracellular cryptococci in macrophages
After phagocytosis, the newly formed phagosome undergoes a
series of vesicle fusion and maturation steps to generate a highly
antimicrobial environment. Many intracellular pathogens, for
exampleMycobacterium tuberculosis, interfere with the maturation
of the phagosome. In contrast, cryptococci apparently do not evade
the acidiﬁed phagosome, as they survive within Lamp1 positive
vesicles at low pH (Johnston and May, 2010; Levitz et al., 1999;
Vandal et al., 2009).
In addition to the classical phagosome maturation pathway, the
cell content recycling pathway of autophagy has been implicated
in the response to a number of pathogens particularly those that
can escape the phagosome (Cemma and Brumell, 2012).
Components of the autophagy pathway were ﬁrst implicated in
the handling of cryptococci in a Drosophila S2 cell RNAi screen
(Qin et al., 2011) and the autophagy effector LC3 has been observed
associated with cryptococcal phagosomes (Nicola et al., 2012).
Conditional macrophage ATG5 deﬁcient mice showed no difference
in survival, although histology of lung lesions showed reduced
inﬂammation (Nicola et al., 2012). There are multiple routes into
activation of autophagy and the lack of strong phenotype may be
explained by compensation of alternative autophagy activation
pathways (Cemma and Brumell, 2012).
C. neoformans is able to proliferate within the macrophage
phagosome (Tucker and Casadevall, 2002; Voelz et al., 2009).
This suggests that C. neoformans is able to inhabit the macrophage
as a protective niche within the host. C. neoformans is also able to
travel from one macrophage to another, whereby the receiving
macrophage accepts the cryptococcal cell in an actin dependant
manner (Alvarez and Casadevall, 2007; Ma et al., 2007). This is a
rare event in vitro that has yet to be observed in vivo. The cause
of this phenomenon, and if it beneﬁts the host or the pathogen is
unknown. The receiving cell may be assisting a potentially mori-
bund macrophage or lateral transfer between macrophages allows
evasion of extracellular host immune responses by cryptococci.
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sion. The mechanism of lysis is unknown. In some cases this
appears to result from intracellular replication leading to large
numbers of intraphagosomal cryptococci causing rupture of the
host cell membrane (Tucker and Casadevall, 2002). Several studies
have identiﬁed that the cryptococcal phagosome is permeabilised,
but by two different mechanisms: Pores to the cytoplasm (Tucker
and Casadevall, 2002) and extracellular phagosome emptying
(Carnell et al., 2011; Johnston and May, 2010). Expulsion of crypto-
cocci is described as a non-lytic escape from macrophages via an
actin independent exocytosis (Alvarez and Casadevall, 2006;
Johnston and May, 2010; Ma et al., 2006). Cryptococci leave the
macrophage without causing damage to the host cell. Again as
with lateral transfer the ultimate beneﬁciary is unknown.
The direct role of all these macrophage parasitic phenomena
in vitro has yet to be demonstrated in pathogenesis but they sup-
port the hypothesis that macrophages are a controlling measure
that require wider host immunity to clear cryptococci. In addition,
macrophages may act as Trojan horses for the dissemination of
cryptococci, a model that has been elegantly supported by showing
that mice infected intravenously with cryptococci within macro-
phages showed much faster dissemination than free yeast
(Charlier et al., 2009).
7. Dendritic cells
As professional antigen presenting cells, dendritic cells lead to
activation of the adaptive immune system, which generates a
speciﬁc immune response to infection, with clear differences in
the roles of DCs and macrophages. However, it should be noted
that there may be signiﬁcant overlap in function and in many cases
the relative contributions of each cell type (and sub-types) in the
responses to cryptococci are not known.
DCs appear to be the primary route by which cryptococcal anti-
gen is presented to stimulate T cells, although a previous study had
suggested that AMs might also be able to stimulate T cells via cryp-
tococcal antigen presentation (Mansour et al., 2006; Syme and
Spurrell, 2002; Vecchiarelli et al., 1994)). Like other phagocytes,
dendritic cells require opsonins to enable high levels of phagocyto-
sis of C. neoformans with contribution from the mannose receptor.
Both complement and anticapsular antibody have been shown to
increase cryptococcal phagocytosis in human dendritic cells,
resulting in TNFa secretion and dendritic cell activation (Syme
and Spurrell, 2002; Kelly et al., 2005). Once phagocytosed, crypto-
cocci are degraded through oxidative and non-oxidative mecha-
nisms, after passage through lysosomes. One interesting example
is a non-enzymatic role for cathepsin B, a degradative enzyme
found in the lysosomal compartment, whereby osmotic lysis leads
to rupture of the cell wall (Hole et al., 2012). Degraded components
are then loaded onto major histocompatibility complex class II
molecules ready for T lymphocyte and ultimately, adaptive
immune system activation (Wozniak et al., 2006). This has been
demonstrated in vivo with a murine model, where pulmonary
cryptococcal infection led to rapid death of mice in which dendritic
cells in addition to alveolar macrophages were depleted, due to
inability to control the infection (Wozniak et al., 2006).
As important as their initial interaction with pathogens as is the
role of DCs and macrophages in recruitment and coordination of
the wider immune response. Much of this stems from the produc-
tion of cytokines and chemokines, and the inﬂuence these have on
the recruitment and activation of other cell types. However, AMs
must ﬁrst initiate this process ﬁrst through recruitment of macro-
phages (and monocytes) and then DCs. The production of macro-
phage chemotactic protein 1, after phagocytosis of cryptococci in
a rat model of chronic pulmonary cryptococcosis, demonstrates
an important step in the initiation of a successful granulomatousresponse (He et al., 2003). Similarly, CCR2 is required for the
recruitment of DCs in response to cryptococcal infection and in
CCR2 deﬁcient mice the inﬂammatory T cell immune response is
immediately disrupted (Osterholzer et al., 2008). Interestingly, in
absence of DCs, in CCR2 deﬁcient mice, there was an increase in
the number of macrophages observed (Osterholzer et al., 2008).
The increase in macrophage numbers may be a direct response
to the failure to transition to the next stage of immune control
(i.e. a failure to dampen the macrophage recruitment signal) or
may be macrophages responding directly to maintain control of
the cryptococcal infection.8. Neutrophils
Neutrophils, like macrophages and dendritic cells, capture and
degrade pathogens and have a particular role in the initiation of
inﬂammation, in response to infection. Thus, neutrophils may be
expected to play an important role in cryptococcal clearance.
However, there is little evidence suggesting that neutrophils are
necessary for control of cryptococcosis as there is no association
between diseases of the neutrophil (e.g. chronic granulomatous
disease, neutropenia) alone being a predisposing factor for crypto-
coccosis, but only in conjunction with additional immune deﬁ-
ciency (e.g. (Hirai et al., 2011)). Mouse studies support this
conclusion, as although neutrophils are able to phagocytose and
degrade C. neoformans, after neutrophil depletion the fungal bur-
den is not enhanced (Mednick et al., 2003; Wozniak et al., 2012).
Furthermore, in mice depleted of neutrophils, survival was
improved, possible through an up-regulation of both Th1 and
Th2 cytokines (Mednick et al., 2003). As a Th1 proﬁle is thought
to be essential in cryptococcal clearance, the combined effect of
both proﬁles may lead to improved cellular clearance with min-
imised host damage, perhaps because, in normal infection, neu-
trophilic responses may actually be detrimental in terms of
organising a Th1 vs Th2 skew.
Despite a potential key role in orchestrating the type of immune
response, neutrophils are primarily active in their use of oxidative
and non-oxidative mechanisms to combat and degrade microbes.
Neutrophils release reactive oxidative species and their intermedi-
ates (hydroxyl and hypochlorite ions) on encountering cryptococci.
However, C. neoformans is able to counteract this host defence,
through production of mannitol, which acts as a scavenger for these
reactive oxygen intermediates, thus reducing their potential for cel-
lular damage (Chaturvedi et al., 1996). Similarly, melanised crypto-
cocci are also resistant to this neutrophil attack (Qureshi et al.,
2011). A non-oxidative host defence delivered by neutrophils is
through production of proteins found within their other granule
types. These proteins, for example defensins (that are not present
in mouse neutrophils (Eisenhauer and Lehrer, 1992)) exert a
degradative effect on cryptococcal cells, in addition to oxidative
mechanisms (Mambula et al., 2000). These anti-cryptococcal
defences highlight how neutrophils are able to combat and degrade
invading cryptococci, despite fungal burden not being neutrophil
dependant.
Neutrophils are activated by contact with cryptococcal compo-
nents, for example the dose dependent release of
pro-inﬂammatory cytokines in response to cryptococcal capsule
(Retini et al., 1996). This indicates a host mechanism that is cap-
able of using the cryptococcal capsule to recognise infection and
may lead to further neutrophil recruitment. Conversely, neu-
trophils are attracted to sites of infection, and CD18 is an adhesion
molecule involved in this step. It is suggested that cryptococcal
capsule molecules are able to bind and functionally inhibit CD18,
leading to impaired attraction of neutrophils to the site of infection
(Dong and Murphy, 1997). This may indicate that C. neoformans
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the release of pro inﬂammatory cytokines.
Individuals with late stage HIV infection do not show differ-
ences in the number neutrophils but speciﬁc functional defects
have been described. For example, reduced expression of CD88, a
C5a receptor, results in a decrease in IL-8 expression in response
to cryptococcal infection and a subsequently reduced inﬂamma-
tory response (Monari and Casadevall, 1999).
9. Eosinophils
Eosinophils are granulocytes that primarily function by releasing
cytotoxic granule proteins (Blanchard and Rothenberg, 2009;
Feldmesser et al., 1997). However, although not professional phago-
cytes, eosinophils are capable of phagocytosis. In a rat cryptococcal
model, eosinophils where shown to phagocytose cryptococci,
become activated andproduce a Th1 proﬁle, indicating a role of acti-
vating the adaptive immune system, shown with an increase in
MHC molecules (Garro et al., 2010). Furthermore, the interaction
with cryptococci down regulated eosinophil NO and H2O2 produc-
tion thatmayhelp to prolong eosinophil life, and therefore their efﬁ-
cacy during infection to act as an APC. Eosinophils activated by
cryptococci were observed to migrate to the spleen and mesenteric
lymph nodes and stimulate speciﬁc T cell and B cell proliferation
(Garro et al., 2011). This suggests a positive role of eosinophils in
the host response to cryptococcal infection in the rat.
In contrast, eosinophil recruitment within genetically suscepti-
ble mice had detrimental effects for the host. Increased eosinophil
recruitment resulted in enhanced IL-5 and led to decreased fungal
clearance and damage of lung epithelial cells (Huffnagle et al.,
1998). Further to this, surfactant protein D, as described above,
promotes the recruitment of eosinophils, through enhancement
of IL-5 production (Holmer et al., 2014).
Eosinophils have been shown to be a major source of Th2 cyto-
kine IL-4 during cryptococcal infection. Eosinophil deﬁcient mice
infected with C. neoformans had fewer Th2 cells and increased
Th1/Th17 cells, in addition to a reduction of inﬂammatory cells
(Piehler et al., 2011). This again indicates a detrimental role of eosi-
nophils, whereby a Th2 proﬁle is induced in their presence. An
interesting clinical observation of an immunocompetent patient
with disseminated C. neoformans infection and elevated eosinophil
levels, suggests that Cryptococcus is able to induce a Th2 proﬁle
that may lead to eosinophilia. However, it was noted that this
patient had an atypical Th2 proﬁle, and drugs used for treatment
may have increased the eosinophil numbers, and this combination
may explain the rarity of this observation (Yamaguchi et al., 2008).
The potential capacity of cryptococci to change the host towards a
Th2 proﬁle may highlight a mechanism of pathogenicity, with an
associated detrimental host response of eosinophil recruitment.
Here the differences between the rat and mouse models is intrigu-
ing and understanding the molecular differences in their immune
response would potentially inform cryptococcal pathogenesis gen-
erally, as well as the importance of eosinophilia and a predominant
Th2 proﬁle in cryptococcal infection, particularly in HIV infected
individuals.
10. B cell and antibody responses to Cryptococcus
Antibodies are generated in response to cryptococcal challenge,
with IgM, IgGand IgAeach isolated fromhumanpatients indescend-
ing order of prevalence (Houpt et al., 1994). Antibodies against cryp-
tococci have been found in adults and children (Abadi and Pirofski,
1999; Chen et al., 1999), indicating cryptococcal infection at a young
age, and that cryptococcal infection is a commonoccurrence.Defects
in antibody responses are seen in immunocompromised individuals,
with B cell repertoire observed in both mouse and human inresponse to glucuronoxylomannan, a major constituent of crypto-
coccal capsule, being depleted in HIV infection (Pirofski, 2001).
Speciﬁc IgM and IgG, but not IgA, against cryptococcal melanin has
been observed after mouse infection (Nosanchuk et al., 1998) and
immune sera were found to only have high afﬁnity to bind to mela-
nised cryptococci. This is interesting as melanin is considered to be
found in the cryptococcal cell wall and suggest that antibodies may
have access to the cell wall during infection. Passive immunisation
with two different monoclonal IgM antibodies to melanin reduced
fungal burden during mouse infection and was able to directly
reduce cryptococcal growth in vitro (Rosas et al., 2001).
As described above, complement and antibody are required for
efﬁcient phagocytosis of C. neoformans in vitro, with potential com-
pensation when one opsonin is missing or impaired. In agreement
with this the reduced complement mediated phagocytosis caused
by increased cryptococcal capsular size is compensated with
increase in antibody mediated phagocytosis, demonstrated with
C5 deﬁcient mice which have an increased antibody response
(Dromer et al., 1989; Zaragoza et al., 2003).
Antibodies have been shown to have a protective effect in leth-
ally infected mice (Fleuridor et al., 1998; Mukherjee et al., 1992),
showing that antibodies are effective as opsonins for C. neoformans.
A mouse model deﬁcient in secreted IgM showed increased death
and fungal burden in the blood and brain. Mice with secreted
IgM adopted a Th1 proﬁle early during infection and had higher
levels of phagocytosis (Marks and Pirofski, 2010). Furthermore, a
B1 B cell deﬁcient murine model showed increased fungal burden
and decreased alveolar macrophage uptake (through decreased
IgM) (Szymczak et al., 2013). This provides an association between
B cell responses, and the effector function of phagocytes using anti-
body for phagocytosis, and suggests that there is requirement for
antibody in the normal clearance of cryptococci. Therapy targeting
B cell and antibody responses is a potentially fruitful area but fur-
ther work is needed to understand the mechanisms involved and
what defects are present in human disease.
11. T cell interactions with cryptococci
The adaptive immune response is unequivocally essential for
host eradication of C. neoformans with the T cell defects seen in,
and so strongly associated with, HIV/AIDS patients (Jarvis and
Harrison, 2007). There are several types of T lymphocytes (T cells)
involved in the host response to C. neoformans, including CD4+,
CD8+ and natural killer T (NKT) cells. In addition to T cells, natural
killer (NK) cells are lymphoid cells that directly interact with cryp-
tococci. CD4+ T cells are key in orchestrating the type of immune
response that results from immune challenge. Naïve CD4+ T cells
are activated and differentiate into different subsets, such as Th1,
Th2 and Th17, due to the cytokines present. Furthermore, once
active CD4+ T cells are able to help B cells, macrophages and
CD8+ T cells, to produce antibodies, activate and proliferate respec-
tively (Luckheeram et al., 2012).
Adaptive immune cells are activated when cryptococci are
recognised after presentation through antigen presenting cells
(APCs). Dendritic cells are likely the primary APC for cryptococci
and are able to promote T cell proliferation signiﬁcantly better
than tissue resident alveolar macrophages (Syme and Spurrell,
2002). In addition, eosinophils, but not macrophages, isolated from
rats were able to promote CD4+ and CD8+ T cell proliferation
through MHC class II and MHC class I molecules respectively
(Garro et al., 2010). This eosinophil mediated T cell expansion led
to Th1 cytokine production and promoted clearance of fungi
(Garro et al., 2010). Within cryptococcal infected CD4+ deﬁcient
mice, an increase in CD8+ proliferation is observed, with increased
TCR diversity, (Lindell et al., 2006, 2005), indicating that CD8+ are
able to function without help from CD4+ cells. Both CD4+ and CD8+
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coccal exposure (Lindell et al., 2006).
Cryptococcal capsular proteins induce a Th2 proﬁle of CD4+
helper cells (Almeida et al., 2001), with this Th2 proﬁle, naïve
CD4+ cell activation is abrogated leading to conditions favourable
for cryptococcal growth through preventing production of pro
inﬂammatory cytokines. Cryptococcal capsule also may disrupt
host T cell responses, through GXM directly inhibiting T cell prolif-
eration, but the mechanism behind this is unclear (Yauch et al.,
2006). Similarly, GXMGal is also shown to inhibit proliferation of
T cell, potentially through the induction of T cell apoptosis
(Pericolini et al., 2006). How cryptococcal capsular modulation of
T cell responses is relevant in disease is not clear, as we do not
know what the encapsulated state of cryptococci during clearance
of infection from the immunocompetent lung. Where this may be
very important is the handling of cryptococci in the immunocom-
promised after CNS invasion where cryptococcal capsule is signif-
icantly enlarged (see below for discussion of T cell functionality
in cryptococcal meningitis).
CD4+, CD8+ and NK cells can bind directly to cryptococci and
act in a fungistatic fashion (Levitz et al., 1994). Cytotoxic CD4+ cells
are able to release granulysin, like CD8+ T cells, to kill C. neofor-
mans and are more effective at killing cryptococcal cells than
CD8+ and NK cells in the blood (Zheng et al., 2007). CD4+ cells also
play a role in CD8+ granulysin mediated cryptococcal degradation,
whereby granulysin is up regulated and released dependent on
CD4+ (Ma et al., 2002).
In addition to CD4+ and CD8+ T cells, there are lymphocytes
that can be considered acting as part of the innate immune system
involved in the host response to C. neoformans: natural killer cells,
natural killer T cells, and cd T cells. Firstly, natural killer cells (NKs)
are able release granules, but unlike CD8+ cells, utilise perforin
rather than granulysin, through a PI3K-ERK1/2 dependent pathway
to cause cryptococcal degradation (Ma et al., 2004; Wiseman et al.,
2007). After degranulation the NK cells are still able to continue
anti cryptococcal activities, due to constitutive expression of per-
forin and granulysin, and rearming of NK cells through direct con-
tact with cryptococcal cells (Ma et al., 2004; Marr et al., 2009).
Recently, NK cells have also been shown to be key in the immune
response to cryptococcal granulomas, having an ability to continue
anti fungal degranulation despite an acidic environment (Islam
et al., 2013). NK cells are thus important in the clearance of cryp-
tococcal cells and granulomas. Natural killer T cells (NKT) are also
able to combat cryptococcal infection. NKT cells are recruited to
mouse lungs after infection, and are able to produce IFNc in
response to cryptococcal challenge, resulting in a Th1 proﬁle ben-
eﬁcial for the host to stop cryptococcal infection (Kawakami et al.,
2001a,b). In contrast, cd T cells do not promote fungal clearance in
the host response to C. neoformans, indicated by mice deﬁcient in
cd T cells that were able to control the fungal infection better than
controls, due to a change towards a Th1 proﬁle (Uezu et al., 2004).
12. T cell regulated immune balance and macrophage
activation: Completing the circle to cryptococcal cell clearance
12.1. T helper cell proﬁle
The host T helper subset and associated cytokines are important
in the progression and outcome of cryptococcal infection with Th1
and Th17 proﬁles associated with clearance of cryptococcal infec-
tion, and Th2 proﬁles associated with cryptococcal dissemination
and host damage. A preferential Th1/Th17 response in comparison
to a Th2 response was shown using an IL 4/IL 13 double knockout
murine model. These mice generated a Th1/Th17 response in
leukocytes and pulmonary lymph nodes against cryptococcal
infection, in comparison to wild type mice that generated a Th2proﬁle. The Th1/Th17 response was shown to be less damaging
to the host through reduced fungal burden, no eosinophilia or air-
way damage and no systemic IgE load (Zhang et al., 2009). Thus, it
appears that generation of a Th2 response from cryptococcal chal-
lenge is detrimental to the host, whilst a Th1/Th17 proﬁle is bene-
ﬁcial. Interestingly, in response to IFNc producing C. neoformans, IL
17A is secreted primarily from neutrophils in mice, and may be
helpful in the clearance of cryptococcal infection (Wozniak et al.,
2011). Similarly, using a murine model, IL 13 a Th2 cytokine, is
shown to be detrimental for the host during cryptococcal infection.
Overexpressing IL 13 mice were more susceptible to infection,
through creation of a Th2 proﬁle whilst inhibiting IL 17 production.
IL 33 receptor deﬁcient mice had better survival and reduced fun-
gal burden in comparison to wild types. Using this mouse model,
IL-33 was shown to be involved in the induction of type 2 lym-
phoid cells, alternatively activated macrophages and the associated
Th2 proﬁle, leading to a better environment for virulent crypto-
cocci (Flaczyk et al., 2013). Subsequent recruitment of eosinophils
and airway inﬂammation were damaging to the host (Muller et al.,
2007). Damage to airways is shown to occur in Th2 proﬁles and is
correlated with production of IgE (Jain et al., 2009). This indicates
that Th2 host damage may in part be caused by an allergic
response. However, Th1/Th17 proﬁles are not sufﬁcient to stop
cryptococcal dissemination, as IL 14/IL 13 knockout mice, which
do not develop Th2 proﬁle, were not protected from dissemination
(Zhang et al., 2009). Therefore, at the level of T cell proﬁling there is
a clear and consistent separation in requirements in pro inﬂamma-
tory pathways. However, greater detail in the positive roles of Th2
responses in resolution of inﬂammation in cryptococcal infection
and the timing of the requirements of the different T helper ele-
ments in still required.
12.2. What changes in immunocompromisation?
In HIV infection, the cytokine proﬁle changes from Th1 to Th2
over time (Altfeld et al., 2000), and therefore the host immune
environment becomes more favourable to cryptococcal infection.
HIV affects the determination of the Th1 vs Th2 proﬁle, as both
increased viral load and decreased CD4+ cell count lead to promi-
nence of IL4 over IFNc (Altfeld et al., 2000). Furthermore, CD4+ T
cell granulysin mediated killing of cryptococci is not activated in
cells from HIV patients (Zheng et al., 2007). A murine model of
HIV infected with Cryptococcus produced reduced levels of
chemokines CCL2 and CCL5, which are immune cell attractants,
in comparison to non-infected mice (Leongson and
Cousineau-Côté, 2013). Thus, HIV infection may lead to speciﬁc
innate immune cell recruitment defects as well as general immune
imbalance and this will further reduced host capability to combat
Cryptococcus.
Recently, anti granulocyte macrophage colony stimulating fac-
tor (GMCSF) autoantibodies have been implicated as a risk factor
for cryptococcal meningitis in HIV negative patients (Rosen et al.,
2013). Anti GMCSF antibodies were previously known to be associ-
ated with the acquired form of alveolar proteinosis, a disease char-
acterised by an ability to process surfactant in the lung leading to
accumulation of material in the alveoli. GMCSF autoantibodies
from a non HIV cryptococcal meningitis patient cohort were able
to inhibit MIP 1a production in monocytes and the phosphoryla-
tion of STAT5. The mechanism of susceptibility of these patients
to cryptococcal meningitis is currently unknown but GMCSF is
likely to play a role in the recruitment and differentiation of mono-
cytes and DCs during cryptococcal infection and these patients
may therefore be unable to activate the secondary responses
required for clearance of cryptococci.
Clearance of cryptococcal cells within the central nervous sys-
tem is possible, and requires Th1 cytokines, in addition to
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Doyle, 2000; Hill and Aguirre, 1994; Huffnagle and McNeil, 1999).
The immune phenotype observed in cryptococcal meningitis
patients is not well understood. A recent study by Jarvis and col-
leagues has begun to address this area: Bymeasuring both systemic
and CNS cytokines and CD4+ responses, and comparing toM. tuber-
culosis and cytomegalovirus responses in the same samples. Using
their method, the speciﬁcity and limitations of the immune
response to CM could be delineated and associated with survival
(Jarvis, seminar presentation 10.1, ICCC9; Jarvis et al., 2013). CD4+
cells speciﬁc to cryptococcal antigen showed little polyfunctional-
ity and were dominated by MIP 1a producing cells with smaller
but equal groups of IFNc and TNFa producing cells. Surviving
patients had higher proportions of IFNc and TNFa producing cells.
In contrast to animal models of cryptococcosis no imbalance of
Th1 and Th2 responses was observed but rather it is the lack of
Th1 responses that was more common with an unfavourable prog-
nosis (Jarvis et al., 2013). However, it should be noted that Th2
responses should not always be categorised, as being detrimental
or unnecessary in handling cryptococcal infection. Changes in
polarisation are seen in mouse pulmonary models, where the M1
and M2 balance shifts over time (Davis et al., 2013). Therefore,
Th2 responses may have important roles at different stages of
human infection e.g. the resolution of inﬂammation after clearance
of infection.12.3. Eradicating cryptococci
Just as macrophages, and subsequently dendritic cells, will ini-
tiate adaptive responses principally through T lymphocytes, the
primary purpose of the T cell response is to eradicate cryptococci
through generation of a suitably antimicrobial environment. As
stated above, in the lung this is almost certainly normally through
a resolving granuloma. In the sites of disseminated infection and,
most importantly, the CNS in cryptococcal meningitis the direct
effectors in clearance are yet to be proven.
Macrophages activated either with Th1/Th17 cytokines or Th2
cytokines had different interactions with cryptococci. A Th1/Th17
proﬁle was shown to activate macrophage anti cryptococcal activ-
ities, causing a reduction of fungal proliferation (Voelz et al., 2009),
thus macrophages require a Th1/Th17 proﬁle to function efﬁ-
ciently. Furthermore, classically activated macrophages are impor-
tant in the clearance of C. neoformans, whereas alternatively
activated macrophages may play a role in the pathogenicity of
cryptococci. Th1 proﬁles classically active macrophages whereas
Th2 cytokines lead to alternatively activated macrophages (Arora
et al., 2011), thus a Th1 proﬁle may lead to the correct type of sub-
sequent macrophage activation, again suggesting Th1 proﬁle is
best to eradicate C. neoformans. The classically activated macro-
phages and dendritic cell lineages acting directly to eradicate cryp-
tococci down stream of Th1 CD4+ responses are currently our most
likely candidates (Hardison et al., 2012, 2010).
It is difﬁcult to measure the direct anti cryptococcal activity of
effector cells in vivo (Hardison et al., 2012). In vitro assessment
showed a small magnitude change in fungicidal activity but it is
likely that ex vivo isolation has a large impact on their phenotype
and therefore fungicidal effectiveness. Interestingly, the classically
activated macrophage phagosome combination of low phagosomal
pH and nitric oxide (NO) in a reconstituted in vitro system showed
a good ability in controlling cryptococcal proliferation (Alspaugh
and Granger, 1991). A recent study gives very good support to this
idea; STAT 1 deﬁcientmice showed an inability to generate a strong
Th1 proﬁle and to produce classically activated M1 macrophages
(Leopold Wager et al., poster presentation 121, ICCC9; Leopold
Wager et al., 2014). Most interestingly the anti fungal activity defectphenotype was associated with severely reduced NO production
from the macrophages isolated from the lungs of infected mice.
13. The immune response to C. gattii
As the major disease causing organism most studies have
focussed on C. neoformans. We know that C. gattii is able to infect
those with apparently normal immune systems suggesting that
there must be large differences in the immune response to this
species. One intriguing difference is that C. gattii generally has a
reduced ability to grow within macrophages than C. neoformans
(Voelz et al., 2014). The exception is the hyper proliferative geno-
types isolated from the Vancouver Island Outbreak (VIO; (Ma et al.,
2009)) and elsewhere in North America (Byrnes et al., 2010;
Springer et al., 2014). These hyper proliferative strains show
changes in mitochondrial gene expression and have a tubular
mitochondria phenotype that closely correlates with macrophage
parasitism and virulence in a mouse model (Ma et al., 2009).
Recently, this has been shown to be dependent on the reactive oxy-
gen species (ROS) response of host macrophages (May and Voelz,
seminar presentation 8.4, ICCC9; Voelz et al., 2014). Inhibition of
ROS production in macrophages was sufﬁcient to block the
increased intracellular proliferation of the VIO strains i.e. a host
antimicrobial response is required for maximal virulence of the
pathogen. How these strains are better able to proliferate in macro-
phages is unclear but this is a phenomenon that appears to func-
tion through modulating the host phagosome, since coinfection
of hyper and hypo proliferative strains together leads to a hyper
proliferation phenotype conferred to both infecting strains.
Theprimary immuneresponse toC. gattii is still unclearwithboth
a hyper andhypo inﬂammatory response reported and there is some
evidence from mouse models that C. gattii may more readily cause
pulmonary infection than spread to the CNS (Ngamskulrungroj
et al., 2012). In vitro stimulation of monocytes demonstrated higher
levels of inﬂammatory cytokines, while the pulmonary immune
response to a VIO strain was poor in comparison to a non VIO and
to a C. neoformans strain when assessed by histology (Okubo et al.,
2013). Fewer Th1/Th17 lymphocytes are present in the lungs of C.
gattii infectedmice (Angkasekwinai et al., 2014) and there is reduced
levels neutrophil inﬁltration in comparison to C. neoformans infec-
tion (Cheng et al., 2009). However, immunisation with C. gattii cell
wall or cytoplasmic components can confer a protective response
to subsequent C. gattii infection (Chaturvedi et al., 2014).
Mice deﬁcient in C1q or C3 or depletion of complement with
cobra venom factor showed overwhelming lung fungal burden
after infection with C. gattii (Mershon et al., 2009). C. gattii is a able
to disrupt dendritic cell maturation by blocking TNFa release
(Huston et al., 2013). In this case DCs are not activated and this
leads to subsequent non activation of further TNFa secretion, anti-
gen presentation and reduced T lymphocyte proliferation. This is
further supported with TNFa induction or addition of exogenous
TNFa restoring DC functions. The resulting absence of adaptive
response may therefore enable infection within immune compe-
tent hosts by C. gattii (Huston et al., 2013). Finally, it is important
to note that there may be cryptic immune pathology in those that
are infected with C. gattii. A recent study has also identiﬁed GMCSF
autoantibodies as a risk factor for C. gattii and this highlights that
further work is needed to understand differences in both host
and pathogen in C. gattii infection (Kwon-Chung et al., seminar pre-
sentation 5.1, ICCC9; Saijo et al., 2014).
14. Conclusions and perspectives
The intricacy and complexity of the immune response to cryp-
tococci is perhaps, on ﬁrst glance, surprising. As cryptococci are
not obligate human pathogens (or even obligate animal pathogens)
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an animal pathogen. However, Cryptococcus has evolved to exploit
an environmental niche (with its own predator prey relationships)
that has driven survival traits that allow it to thrive in its niche that
also give it advantages in the human body (Bliska and Casadevall,
2009; Steenbergen and Casadevall, 2003). Furthermore, land ani-
mals have been exposed to a wide variety of potentially lethal
microorganism via their respiratory systems for millions of years
and we have evolved many different and interacting defences
against organisms such as Cryptococcus. This constitutes an arms
race; one that we are winning as, although disease burden and
mortality due to respiratory and opportunistic infection are very
high, exposure and subclinical infection must be several orders of
magnitude greater.
Where we are losing, and where cryptococcal disease burden is
centred, is in individuals with compromised immune systems.
Evidence from all areas, clinical, animal models and in vitro exper-
iments, points to the central importance of the macrophage/T cell
axis. Immune defects in T cell development (blood proliferative
disorders), numbers and functionality (HIV infection, immunosup-
pressant treatment) and signalling (antibodies to TNFa) all lead to
increased risk of disseminated cryptococcal infection.
As we have described there are many examples of how crypto-
cocci may be killed by host immune cells but it is still not clear
what the critical mechanism is during clearance of infection and
attempts to recapitulate this in vitro have not been conclusive.
Most likely it will be a combination of mechanism that may be
thought of as a series of barriers to disseminated infection, ones
that are extremely rarely breached except in the case of signiﬁcant
defects in immunity. However, if immune therapy as an adjunct to
antifungal treatment is to be a reality we need to understand the
precise effector pathways that are required.
Animal models have been central to our understanding of the
required immune response to cryptococcal infection for clearance
and what defects dispose to disseminated infection. Clinical data
has been extremely helpful in placing this understanding in the
context of human disease but there is much to be done in this chal-
lenging area. Increasing knowledge of immunity late in infection
would allow us to better manage both the clearance of the large
CNS fungal burden and related pathology both during and after
antifungal treatment.
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